
Lorena Maestre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1793424/publications.pdf Version: 2024-02-01



LODENA MAESTRE

#	Article	IF	CITATIONS
1	CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. Cancers, 2022, 14, 2154.	1.7	1
2	High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. PLoS ONE, 2020, 15, e0229743.	1.1	10
3	Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. American Journal of Human Genetics, 2019, 104, 651-664.	2.6	51
4	Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas. Clinical Cancer Research, 2017, 23, 6315-6324.	3.2	73
5	Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers. Nature Communications, 2016, 7, 13418.	5.8	46
6	The European antibody network's practical guide to finding and validating suitable antibodies for research. MAbs, 2016, 8, 27-36.	2.6	46
7	ChiTaRS 2.1—an improved database of the chimeric transcripts and RNA-seq data with novel sense–antisense chimeric RNA transcripts. Nucleic Acids Research, 2015, 43, D68-D75.	6.5	26
8	CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma. PLoS ONE, 2015, 10, e0125203.	1.1	30
9	BCL7A protein expression in normal and malignant lymphoid tissues. British Journal of Haematology, 2013, 160, 106-109.	1.2	9
10	Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues. Immunology Letters, 2011, 134, 150-156.	1.1	8
11	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica, 2010, 95, 1342-1349.	1.7	128
12	Deregulated Expression of the Polycomb-Group Protein SUZ12 Target Genes Characterizes Mantle Cell Lymphoma. American Journal of Pathology, 2010, 177, 930-942.	1.9	41
13	Expression pattern of XBP1(S) in human B-cell lymphomas. Haematologica, 2009, 94, 419-422.	1.7	27
14	Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia, 2009, 23, 1847-1857.	3.3	87
15	Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood, 2008, 111, 351-358.	0.6	69
16	Generation of a New Monoclonal Antibody Against MALT1 by Genetic Immunization. Hybridoma, 2007, 26, 86-91.	0.5	3
17	Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica, 2007, 92, 1059-1066.	1.7	142
18	Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 2007, 26, 1616-1625.	2.6	130

LORENA MAESTRE

#	Article	IF	CITATIONS
19	Genetic Immunization: A New Monoclonal Antibody for the Detection of BCL-6 Protein in Paraffin Sections. Journal of Histochemistry and Cytochemistry, 2006, 54, 31-38.	1.3	12
20	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica, 2006, 91, 467-74.	1.7	70
21	FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia, 2005, 19, 2247-2253.	3.3	131
22	Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. European Journal of Immunology, 2005, 35, 1681-1691.	1.6	528
23	FOXP3 Expression in B and T Cell Lymphomas Blood, 2005, 106, 4503-4503.	0.6	0
24	Simultaneous detection of the immunophenotypic markers and genetic aberrations on routinely processed paraffin sections of lymphoma samples by means of the FICTION technique. Leukemia, 2004, 18, 348-353.	3.3	28